(thirdQuint)Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE).

 The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.

3-30 mg/kg, in adult patients who have SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

 The secondary objective of this study is to describe the pharmacokinetics and potential immunogenicity of MEDI-545.

.

 Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)@highlight

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.

3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

